



(51) International Patent Classification:

C07K 14/74 (2006.01) *C12N 5/10* (2006.01)
A61P 31/00 (2006.01) *C12Q 1/02* (2006.01)
A61P 35/00 (2006.01) *G01N 33/566* (2006.01)
C12N 15/12 (2006.01)

(21) International Application Number:

PCT/IB2020/057175

(22) International Filing Date:

29 July 2020 (29.07.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/880,496 30 July 2019 (30.07.2019) US
 63/029,111 22 May 2020 (22.05.2020) US

(71) Applicant: **UNIVERSITY HEALTH NETWORK**
 [CA/CA]; 101 College Street, Unit 150, Toronto, Ontario
 M5G-1L7 (CA).


(72) Inventors: **HIRANO, Naoto**; 101 College Street, Unit 150,
 Toronto, Ontario M5G-1L7 (CA). **NAKATSUGAWA,**

Munehide; 101 College Street, Unit 150, Toronto, Ontario
 M5G-1L7 (CA). **YAMASHITA, Yuki**; 101 College Street,
 Unit 150, Toronto, Ontario M5G-1L7 (CA). **RAHMAN,**
Muhammed Aashiq; 101 College Street, Unit 150, Toron-
 to, Ontario M5G-1L7 (CA). **GUO, Tingxi**; 101 College
 Street, Unit 150, Toronto, Ontario M5G-1L7 (CA).

(81) Designated States (unless otherwise indicated, for every
 kind of national protection available): AE, AG, AL, AM,
 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
 HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
 KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
 NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
 SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
 TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
 kind of regional protection available): ARIPO (BW, GH,
 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: MHC CLASS II MOLECULES AND METHODS OF USE THEREOF



(57) Abstract: The present disclosure is directed to HLA class II molecules having a higher affinity for CD4 than naturally occurring HLA class II molecules. In certain aspects, the HLA class II molecule comprises a DP beta chain having (i) an amino acid other than leucine at a position corresponding to amino acid residue 112 of SEQ ID NO: 1, (ii) an amino acid other than valine at a position corresponding to amino acid residue 141 of SEQ ID NO: 1, (iii) or both (i) and (ii). Certain aspects of the present disclosure are directed to nucleic acid molecules encoding the HLA class II molecules, vectors comprising the nucleic acid molecule, cells comprising the same, and methods of use thereof.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed
contained color or greyscale and is available for download
from PATENTSCOPE*